Oral Surgeons Are Pulling Surgical Referrals Back In-House

Oral and maxillofacial surgery is the best-paid corner of dentistry, with a median of $352,220 a year against a national pool of only 5,600 practitioners, according to the U.S. Bureau of Labor Statistics. It is also the corner of dentistry whose revenue depends most heavily on a decision made in somebody else's operatory, which is why the quiet collapse of the implant referral is the most underpriced risk on both sides of the slip.

Here's our call, and plenty of owners will argue with it: the GP-to-surgeon implant referral is becoming the exception rather than the default, and any practice still modeling implant economics on the old split is carrying an unpriced liability. If you're a general dentist, protecting the relationship is the wrong instinct. Pick a side of the case and own it end to end. A referral pad was never a moat. It's a month-to-month lease, and the tenant on the other side just raised capital.

41% Is the Whole Story

Peer-reviewed survey work published in Oral Health & Preventive Dentistry and indexed on PMC puts a number on something most owners have felt but not measured: 41% of general dental practitioners now perform the surgical phase of implant placement themselves. Only 59% still refer it out. And 93% keep the prosthetic phase in-house, which has been true for a while.

The comparison that matters is historical. In comparable surveys from the 2000s, only 10% to 16% of GPs were placing fixtures themselves. The in-house surgical share has therefore grown by roughly 2.6 to 4 times in two decades. That is not drift. That is a boundary moving.

Now put it against supply on the specialist side. BLS projects oral and maxillofacial surgeons to grow 6% to 5,900 by 2035, a net addition of 300 surgeons over a decade. Nobody is getting squeezed by 300 new surgeons. The pressure runs the other direction: the people who used to generate the referral are increasingly doing the case, and surgeons have responded the only way the math allows, by backfilling the restorative half they used to hand back and by going straight to the patient. Both sides are now quietly annexing the other's territory while still calling each other partners.

What Most Owners Get Wrong About the Referral Pad

The specific mistake belongs to the mid-career GP owner with a stable restorative practice and a surgeon they've used for a decade. They measure the relationship by cases sent. They can tell you, roughly, how many implant and third-molar cases went out last year. Almost none of them can tell you the restorative capture rate on those cases: of the fixtures they referred, what percentage came back for the abutment and crown in their chair.

That is the only number in the relationship that pays you. And it is the number a consolidator-owned surgical group is explicitly working to reduce, because a surgical practice with restorative chairs in the building has a better per-case margin and a better story for its next lender.

Run the leak. A practice referring 50 implant cases a year at an average restorative fee of $2,100 and a 70% capture rate collects $73,500 on the back half. The 15 cases that never come back are $31,500 of production that walked out on a referral slip you wrote. Most owners book that as attrition or as patients moving away. It isn't. It's a competitor's marketing working on your patient list, funded by the goodwill you extended.

The second mistake belongs to the surgeon: treating the GP referral base as a fixed asset and taking a multiple on earnings it generates. More on that below, because it's the more expensive error.

Fifty Cases, $54,000 of New Cost, $115,000 of New Collections

Take a GP owner currently referring 50 straightforward single-unit implant cases a year, no advanced grafting, no medically complex patients, CBCT already in the building. They keep the crowns. They want to know whether placing the fixture pencils out.

Revenue side first. At an average collected surgical fee of $2,300 per case, 50 cases is $115,000 of new collections.

Cost side, year one and honest:

• Implant surgical continuum, tuition and travel: $18,000
• Planning software plus per-case surgical guides at $240 a case: $12,000
• Fixtures and surgical components at $380 a case: $19,000
• Added assistant hours and turnover time on surgical days: $5,000

That totals $54,000 of new cost against the $115,000. Net first-year contribution is $61,000. Every dollar of new cost returns about $2.13 of collections.

Two things about that number. First, it is a first-year figure carrying the full $18,000 of tuition, so year two looks materially better once training drops out and only the per-case costs remain. Second, it is fragile in exactly one place: case selection. Place twenty cases that belonged in a surgeon's chair and the $61,000 evaporates into remakes, failed integrations, chair time you don't bill, and one conversation with a patient's attorney. The economics of in-housing surgery are good. The economics of in-housing the wrong surgery are catastrophic, and no CE weekend changes that.

Our view: if your implant volume is under about 25 cases a year, don't buy the continuum. Buy the referral discipline instead and fight for the back half of the case. The fixed cost of becoming competent doesn't amortize at low volume, and a half-trained placing dentist is the worst possible position in this market.

96 Deals a Year Means You're Negotiating With a Balance Sheet

The reason this boundary is moving now, rather than in 2012, is capital. ADA News reports private-equity affiliation among dentists rising from 6.6% in 2015 to 12.8% in 2021, with affiliation among specialists more than doubling over that period and annual PE dental transactions jumping from fewer than 20 a year between 2004 and 2015 to 96 in 2021.

Oral surgery specifically is in the thick of it. Group Dentistry Now's May 2025 roundup documents OMS360 acquiring Pittsburgh Oral Surgery and Winter Haven Oral Surgery, U.S. Oral Surgery Management partnering with Sierra Foothills OMS and Shenandoah Oral & Facial Surgery, and Oakpoint expanding Nu Image Surgical, against a U.S. DSO market that Grand View Research sizes at $26.9B in 2023 and projects at $76.2B by 2030, a 16.4% compound annual growth rate.

What that means operationally: the surgeon you refer to may no longer be the person deciding whether your crown comes back. A platform with 40 surgical locations has a central marketing budget, a patient-acquisition cost target, and a restorative revenue line to defend. Reciprocity is a solo-practice value. It is not a line item in a management services agreement.

Patients Picked the Surgeon Before You Did

The thing that makes this asymmetric is that the surgeons already have the consumer brand. National surveys cited by AAOMS, run from 2017 through 2022 at a 95% confidence level, found 76% of mothers of teens and 77% of young adults would choose an oral and maxillofacial surgeon for wisdom teeth removal, and 59% of baby boomers prefer an OMS for dental implants. Five consecutive years of being the public's provider of choice.

Read that as a GP owner and it cuts both ways. Your implant patient, especially if they're over 60, has a mild prior preference for someone else doing the surgery. That is not a reason to skip in-housing. It is a reason to understand that if you place fixtures, you are competing on trust, not just on convenience, and your case presentation has to carry that weight. "I can do it here" is not an argument. "I've placed 180 of these, here's the CBCT, here's what I'd refer out and why" is.

If You're the Surgeon Planning to Sell

This is where the dollars get large. Take a surgical practice doing 380 implant placements a year at $2,300, which is $874,000 of implant surgical revenue. Assume in-housing by referring GPs takes 20% of that over the next three years, a conservative read given the 41% figure. That's $174,800 of revenue gone. At a 45% contribution margin on marginal surgical cases, that's $78,660 of EBITDA. At a 7x multiple, it's $550,620 of enterprise value.

We wouldn't sign a letter of intent priced on referral-derived implant EBITDA without a structure that shares that risk. If a buyer is paying 7x on earnings sourced from 60 referral relationships they can't contract, they're pricing an annuity that is structurally eroding, and when it erodes, the earnout is where the loss lands. Push the mix. Revenue from patients who found you directly, from third molars and pathology and trauma, from restorative done in your own building, deserves a different multiple than revenue that depends on 25 GPs continuing to be generous.

What Would Move Us Off This Call

Two things. If the next wave of survey data shows in-house surgical rates plateauing near 41% rather than climbing toward 55% or 60%, the boundary has found its natural limit and the referral relationship is more durable than we're arguing. And if complication and failure rates on GP-placed fixtures start showing up in malpractice and remake data at scale, the market will self-correct fast and the specialists will get their volume back with interest. We're watching restorative capture rates most closely, because that's the leading indicator: when surgical groups start adding restorative chairs in markets where they already dominate, the handshake era is formally over.

Pull the Referral Ledger This Week

Count every implant and third-molar case you referred in the last 12 months, then count how many came back for restorative. That one percentage tells you whether you have a partner or a competitor. If capture is under 80%, call the surgeon and ask directly what changed, and if the answer involves a management company, start modeling the in-house case with your real chair cost, not a vendor's spreadsheet. If you're the surgeon, do the inverse: pull the share of your production that traces to referrals you can't contract, and know that number before anyone shows you a multiple.

Before you commit $54,000 to in-housing anything, know what an hour in your surgical chair actually costs you once fixed overhead is loaded in. Our free overhead calculator breaks your cost per chair hour down by category so you can test a $2,300 surgical fee against the real number instead of a guess, and see whether 50 cases a year clears your fixed base. Run your own numbers and compare your implant-day economics against the practices already on the other side of this shift.